JAMA Oncology
Papers 2,741
1 page of 275 pages (2,741 results)
#1Kalpana Parvathaneni (University of Pennsylvania)H-Index: 2
#2Kyabeth Torres-Rodriguez (University of Pennsylvania)
Last. Vijay G. Bhoj (University of Pennsylvania)H-Index: 17
view all 7 authors...
#1Aaron J. Katz (KU: University of Kansas)H-Index: 6
#2Kevin Haynes (Wilmington University)H-Index: 37
Last. Ronald C. Chen (KU: University of Kansas)H-Index: 10
view all 6 authors...
#1Steven Sorscher (Wake Forest University)H-Index: 14
#1Vishal Navani (Tom Baker Cancer Centre)
#2Daniel Yick Chin Heng (Tom Baker Cancer Centre)H-Index: 33
Importance null The treatment landscape of metastatic renal cell carcinoma has evolved rapidly over the last decade. Recent combination approaches heralded by targeting immune checkpoints cytotoxic T-lymphocyte antigen 4 and programmed death-1 (PD-1) have been followed in consecutive years by protocols targeting vascular endothelial growth factor receptor, PD-1, and programmed death ligand-1. The differences in baseline patient characteristics, statistical plans, follow-up length, biomarker-deri...
#1Thomas W. P. Friedl (University of Ulm)H-Index: 22
#2Wolfgang Janni (University of Ulm)H-Index: 67
Last. Brigitte Rack (University of Ulm)H-Index: 11
view all 3 authors...
#1Christopher J.D. Wallis (University of Toronto)H-Index: 24
#2Zhiguo Zhao (VUMC: Vanderbilt University Medical Center)H-Index: 10
Last. Daniel A. Barocas (VUMC: Vanderbilt University Medical Center)H-Index: 54
view all 20 authors...
Importance null Treatment-related regret is an integrative, patient-centered measure that accounts for morbidity, oncologic outcomes, and anxiety associated with prostate cancer diagnosis and treatment. null Objective null To assess the association between treatment approach, functional outcomes, and patient expectations and treatment-related regret among patients with localized prostate cancer. null Design, setting, and participants null This population-based, prospective cohort study used 5 Su...
#1Emmanouil Fokas (DKFZ: German Cancer Research Center)H-Index: 39
view all 126 authors...
Importance null Total neoadjuvant therapy has been increasingly adopted for multimodal rectal cancer treatment. The optimal sequence of chemoradiotherapy (CRT) and chemotherapy needs to be established. null Objective null To report the long-term results of the secondary end points prespecified in the Randomized Phase 2 Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy (CAO/ARO/AIO-12 trial) for Locally Advanced Rectal Cancer. null Design, Settin...
#1Randy A. Jones (UVA: University of Virginia)H-Index: 18
#1Michael S. Leapman (Yale University)H-Index: 17
#2Rong Wang (Yale University)H-Index: 22
Last. Xiaomei Ma (Yale University)H-Index: 46
view all 8 authors...
Importance null In April 2017, the US Preventive Services Task Force (USPSTF) published a draft guideline that reversed its 2012 guidance advising against prostate-specific antigen (PSA)–based screening for prostate cancer in all men (grade D), instead endorsing individual decision-making for men aged 55 to 69 years (grade C). null Objective null To evaluate changes in rates of PSA testing after revisions in the USPSTF guideline on prostate cancer screening. null Design, Setting, and Participant...
#1Tyler B Kratzer (ACS: American Cancer Society)
#2Rebecca L. Siegel (ACS: American Cancer Society)H-Index: 68
Last. Ahmedin Jemal (ACS: American Cancer Society)H-Index: 139
view all 6 authors...
Top fields of study
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.